The CF gastrointestinal microbiome: Structure and clinical impact

Geraint Rogers, Michael R. Narkewicz, Lucas R. Hoffman

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders. Pediatr Pulmonol. 2016;51:S35–S44.

LanguageEnglish
PagesS35-S44
JournalPediatric Pulmonology
Volume51
DOIs
Publication statusPublished - 1 Oct 2016

Keywords

  • antibiotic therapy
  • cystic fibrosis (CF)
  • gastrointestinal
  • microbiome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Rogers, Geraint ; Narkewicz, Michael R. ; Hoffman, Lucas R. / The CF gastrointestinal microbiome : Structure and clinical impact. In: Pediatric Pulmonology. 2016 ; Vol. 51. pp. S35-S44.
@article{f4d863c83b374b519a6b1d573e0debfc,
title = "The CF gastrointestinal microbiome: Structure and clinical impact",
abstract = "The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders. Pediatr Pulmonol. 2016;51:S35–S44.",
keywords = "antibiotic therapy, cystic fibrosis (CF), gastrointestinal, microbiome",
author = "Geraint Rogers and Narkewicz, {Michael R.} and Hoffman, {Lucas R.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/ppul.23544",
language = "English",
volume = "51",
pages = "S35--S44",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",

}

The CF gastrointestinal microbiome : Structure and clinical impact. / Rogers, Geraint; Narkewicz, Michael R.; Hoffman, Lucas R.

In: Pediatric Pulmonology, Vol. 51, 01.10.2016, p. S35-S44.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The CF gastrointestinal microbiome

T2 - Pediatric Pulmonology

AU - Rogers, Geraint

AU - Narkewicz, Michael R.

AU - Hoffman, Lucas R.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders. Pediatr Pulmonol. 2016;51:S35–S44.

AB - The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders. Pediatr Pulmonol. 2016;51:S35–S44.

KW - antibiotic therapy

KW - cystic fibrosis (CF)

KW - gastrointestinal

KW - microbiome

UR - http://www.scopus.com/inward/record.url?scp=84988535654&partnerID=8YFLogxK

U2 - 10.1002/ppul.23544

DO - 10.1002/ppul.23544

M3 - Review article

VL - 51

SP - S35-S44

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

ER -